Ipamorelin: Receptor Selectivity and Research Profile
A review of ipamorelin, a pentapeptide growth hormone secretagogue, with focus on its receptor selectivity profile and what pre-clinical and early clinical studies have examined.
Ipamorelin is a synthetic pentapeptide (five amino acids) developed by Novo Nordisk in the 1990s as part of a program investigating growth hormone secretagogues. Its sequence — Aib-His-D-2Nal-D-Phe-Lys-NH₂ — incorporates non-natural amino acids that confer resistance to peptidase degradation and influence receptor binding characteristics.
Why Selectivity Is Central to Ipamorelin Research
The growth hormone secretagogue receptor (GHS-R1a) is not the only receptor that GHS-class peptides interact with. Earlier GHSPs such as GHRP-6 and GHRP-2 were observed in animal and human studies to stimulate not only GH release but also prolactin, ACTH, and cortisol — suggesting off-target receptor activity or downstream signaling overlap.
Ipamorelin was specifically developed with selectivity in mind. In vitro receptor binding studies reported in the original Novo Nordisk characterization papers (Raun et al., 1998) found that ipamorelin had high selectivity for GHS-R1a relative to other GPCRs tested. Animal studies comparing ipamorelin to GHRP-6 at equipotent GH-releasing doses reported significantly less effect on cortisol and ACTH release for ipamorelin.
This selectivity profile has made ipamorelin a subject of continued research interest and is frequently cited as a distinguishing feature from older GHS compounds. However, researchers should note that receptor selectivity data is not automatically predictive of clinical safety or tolerability — it describes binding affinity, not the full pharmacological consequence.
Structural Features That Influence Activity
Ipamorelin's non-natural amino acid inclusions are instructive for understanding how synthetic peptides are designed for research purposes:
- Aib (α-aminoisobutyric acid): This non-natural α-methyl amino acid confers conformational rigidity and is commonly used in peptide chemistry to improve stability against proteolytic degradation.
- D-2Nal and D-Phe: D-amino acids are mirror images of natural L-amino acids. Many peptidases cannot cleave bonds involving D-amino acids, extending the half-life of synthetic peptides.
- C-terminal amidation (-NH₂): Amidation of the carboxyl terminus reduces susceptibility to carboxypeptidase degradation.
These structural features explain why synthetic research peptides often have longer observed half-lives than natural peptide ligands.
What Animal Studies Have Examined
Pre-clinical research on ipamorelin has examined several parameters:
GH pulse characteristics: Rodent studies have measured GH pulse amplitude and area under the curve (AUC) following ipamorelin administration. Findings have generally been consistent with GHS-R1a-mediated pituitary stimulation.
IGF-1 levels: Some animal studies have reported that repeated ipamorelin administration may be associated with increased plasma IGF-1 levels, which is the primary peripheral mediator of GH's anabolic signaling. The dose-response relationship and temporal dynamics have been characterized in rat models.
Cortisol and ACTH sparing: As noted in the selectivity discussion, comparative animal studies have reported that ipamorelin produces less ACTH/cortisol release than GHRP-6 at equieffective GH-releasing doses. This finding has been replicated in at least some independent studies, which adds to its credibility, though the comparison has not been rigorously established in human clinical trials.
Body composition: Longer-duration animal studies have examined whether sustained ipamorelin administration is associated with changes in lean mass and fat mass. Results have been variable depending on model, dose, and duration.
Human Research
Human data on ipamorelin is limited. Novo Nordisk did advance ipamorelin to Phase II clinical trials for postoperative ileus (a condition involving reduced bowel motility following surgery), based on evidence of GHS-R expression in the gastrointestinal tract. This trial (and related GI motility applications) represented a different mechanistic rationale than the GH-related applications typically discussed in research contexts.
No published human data on the GH-releasing effects of ipamorelin meets the standard of a large randomized controlled trial as of this writing.
Half-Life and Administration Context
Ipamorelin's plasma half-life has been reported at approximately 2 hours in animal pharmacokinetic studies. This is relevant for researchers designing protocols, as the pulsatile nature of GH secretion means timing of administration relative to natural GH pulse cycles may affect observed outcomes.
Subcutaneous and intravenous routes have been used in animal studies. Oral bioavailability of ipamorelin, as with most peptides of this size, is expected to be very low due to gastrointestinal peptidase activity, though this has not been extensively characterized.
Summary of Evidence Quality
| Evidence Type | Status |
|---|---|
| Receptor binding data | Published in vitro |
| Animal GH release | Multiple published studies |
| Animal IGF-1 effects | Limited published studies |
| Human GH release (RCT) | Not published as of writing |
| Long-term human safety | No published data |
Researchers evaluating ipamorelin claims should position all statements within this evidence framework.
References
- 1.Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 [PubMed]